Lexicon Pharmaceuticals, Inc. Board of Directors

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Mr. Dixon Terry

Mr. Dixon Terry

Vice President of Compliance

Dr. Alan J. Main Ph.D.

Dr. Alan J. Main Ph.D.

Executive Vice President of Innovation & Chemical Sciences

Ms. Kristen L. Alexander

Ms. Kristen L. Alexander

Vice President of Finance & Accounting

Dr. Craig B. Granowitz M.D., Ph.D.

Dr. Craig B. Granowitz M.D., Ph.D.

Senior VP & Chief Medical Officer

Ms. Desiree Gendron

Ms. Desiree Gendron

Vice President of Sales & Training

Ms. Lisa M. DeFrancesco

Ms. Lisa M. DeFrancesco

Vice President of Investor Relations & Corporate Communications

Ms. Carrie Siragusa

Ms. Carrie Siragusa

Vice President of Marketing

Mr. Brian T. Crum

Mr. Brian T. Crum

Senior VP, General Counsel & Secretary

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.